The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.
Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal therapeutic activity. To support clinical studies of combination therapy, 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake measured by Positron Emission Tomography (PET) was evaluated...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3858267?pdf=render |
id |
doaj-d9f447118f4f4c868e1e77719ad9955a |
---|---|
record_format |
Article |
spelling |
doaj-d9f447118f4f4c868e1e77719ad9955a2020-11-25T02:12:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8176310.1371/journal.pone.0081763The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice.Emma J HaagensenHuw D ThomasIan WilsonSuzannah J HarnorSara L PayneTommy RennisonKate M SmithRoss J MaxwellDavid R NewellCombined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal therapeutic activity. To support clinical studies of combination therapy, 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake measured by Positron Emission Tomography (PET) was evaluated as a non-invasive surrogate response biomarker in pre-clinical models. The in vivo anti-tumour efficacy and PK-PD properties of the MEK inhibitor PD 0325901 and the PI3K inhibitor GDC-0941, alone and in combination, were evaluated in HCT116 and HT29 human colorectal cancer xenograft tumour-bearing mice, and [(18)F]-FLT PET investigated in mice bearing HCT116 xenografts. Dual targeting of PI3K and MEK induced marked tumour growth inhibition in vivo, and enhanced anti-tumour activity was predicted by [(18)F]-FLT PET scanning after 2 days of treatment. Pharmacodynamic analyses using the combination of the PI3K inhibitor GDC-0941 and the MEK inhibitor PD 0325901 revealed that increased efficacy is associated with an enhanced inhibition of the phosphorylation of ERK1/2, S6 and 4EBP1, compared to that observed with either single agent, and maintained inhibition of AKT phosphorylation. Pharmacokinetic studies indicated that there was no marked PK interaction between the two drugs. Together these results indicate that the combination of PI3K and MEK inhibitors can result in significant efficacy, and demonstrate for the first time that [(18)F]-FLT PET can be correlated to the improved efficacy of combined PI3K and MEK inhibitor treatment.http://europepmc.org/articles/PMC3858267?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Emma J Haagensen Huw D Thomas Ian Wilson Suzannah J Harnor Sara L Payne Tommy Rennison Kate M Smith Ross J Maxwell David R Newell |
spellingShingle |
Emma J Haagensen Huw D Thomas Ian Wilson Suzannah J Harnor Sara L Payne Tommy Rennison Kate M Smith Ross J Maxwell David R Newell The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. PLoS ONE |
author_facet |
Emma J Haagensen Huw D Thomas Ian Wilson Suzannah J Harnor Sara L Payne Tommy Rennison Kate M Smith Ross J Maxwell David R Newell |
author_sort |
Emma J Haagensen |
title |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. |
title_short |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. |
title_full |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. |
title_fullStr |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. |
title_full_unstemmed |
The enhanced in vivo activity of the combination of a MEK and a PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer xenograft tumour-bearing mice. |
title_sort |
enhanced in vivo activity of the combination of a mek and a pi3k inhibitor correlates with [18f]-flt pet in human colorectal cancer xenograft tumour-bearing mice. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Combined targeting of the MAPK and PI3K signalling pathways in cancer may be necessary for optimal therapeutic activity. To support clinical studies of combination therapy, 3'-deoxy-3'-[(18)F]-fluorothymidine ([(18)F]-FLT) uptake measured by Positron Emission Tomography (PET) was evaluated as a non-invasive surrogate response biomarker in pre-clinical models. The in vivo anti-tumour efficacy and PK-PD properties of the MEK inhibitor PD 0325901 and the PI3K inhibitor GDC-0941, alone and in combination, were evaluated in HCT116 and HT29 human colorectal cancer xenograft tumour-bearing mice, and [(18)F]-FLT PET investigated in mice bearing HCT116 xenografts. Dual targeting of PI3K and MEK induced marked tumour growth inhibition in vivo, and enhanced anti-tumour activity was predicted by [(18)F]-FLT PET scanning after 2 days of treatment. Pharmacodynamic analyses using the combination of the PI3K inhibitor GDC-0941 and the MEK inhibitor PD 0325901 revealed that increased efficacy is associated with an enhanced inhibition of the phosphorylation of ERK1/2, S6 and 4EBP1, compared to that observed with either single agent, and maintained inhibition of AKT phosphorylation. Pharmacokinetic studies indicated that there was no marked PK interaction between the two drugs. Together these results indicate that the combination of PI3K and MEK inhibitors can result in significant efficacy, and demonstrate for the first time that [(18)F]-FLT PET can be correlated to the improved efficacy of combined PI3K and MEK inhibitor treatment. |
url |
http://europepmc.org/articles/PMC3858267?pdf=render |
work_keys_str_mv |
AT emmajhaagensen theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT huwdthomas theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT ianwilson theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT suzannahjharnor theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT saralpayne theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT tommyrennison theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT katemsmith theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT rossjmaxwell theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT davidrnewell theenhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT emmajhaagensen enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT huwdthomas enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT ianwilson enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT suzannahjharnor enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT saralpayne enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT tommyrennison enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT katemsmith enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT rossjmaxwell enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice AT davidrnewell enhancedinvivoactivityofthecombinationofamekandapi3kinhibitorcorrelateswith18ffltpetinhumancolorectalcancerxenografttumourbearingmice |
_version_ |
1724907541429747712 |